Unknown

Dataset Information

0

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.

ABSTRACT: Glycogen synthase kinase-3 beta (GSK-3?), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3? inhibitor, 9-ING-41, currently in clinical studies in patients with advanced cancer, in bladder cancer cell lines. We found that treatment with 9-ING-41 leads to cell cycle arrest, autophagy and apoptosis in bladder cancer cells. The autophagy inhibitor chloroquine potentiated the antitumor effects of 9-ING-41 when tested in combination studies. Our findings also demonstrate that 9-ING-41 enhanced the growth inhibitory effects of gemcitabine or cisplatin when used in combination in bladder cancer cells. Finally, we found that 9-ING-41 sensitized bladder cancer cells to the cytotoxic effects of human immune effector cells. Our results provide a rationale for the inclusion of patients with advanced bladder cancer in clinical studies of 9-ING-41.

SUBMITTER: Kuroki H 

PROVIDER: S-EPMC6934761 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer.

Kuroki Hiroo H   Anraku Tsutomu T   Kazama Akira A   Bilim Vladimir V   Tasaki Masayuki M   Schmitt Daniel D   Mazar Andrew P AP   Giles Francis J FJ   Ugolkov Andrey A   Tomita Yoshihiko Y  

Scientific reports 20191227 1

Glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase, has been identified as a potential therapeutic target in human bladder cancer. In the present study, we investigated the antitumor effect of a small molecule GSK-3β inhibitor, 9-ING-41, currently in clinical studies in patients with advanced cancer, in bladder cancer cell lines. We found that treatment with 9-ING-41 leads to cell cycle arrest, autophagy and apoptosis in bladder cancer cells. The autophagy inhibitor chloroquine  ...[more]

Similar Datasets

Unknown 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells.
| S-EPMC8696016 | biostudies-literature
Transcriptomics 9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy in KRAS mutated colorectal cancer
2021-10-31 | GSE184125 | GEO
Unknown Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma.
| S-EPMC9272832 | biostudies-literature
Unknown Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.
| S-EPMC5496477 | biostudies-literature
Unknown GSK-3β in Pancreatic Cancer: Spotlight on 9-ING-41, Its Therapeutic Potential and Immune Modulatory Properties.
| S-EPMC8301062 | biostudies-literature
Unknown Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.
| S-EPMC6984786 | biostudies-literature
Unknown Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignancies.
| S-EPMC8989389 | biostudies-literature
Genomics 9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy in KRAS mutated colorectal cancer
| PRJNA763229 | ENA
Unknown GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.
| S-EPMC5777742 | biostudies-literature
Unknown AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
| S-EPMC3183744 | biostudies-literature